Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Procainamide Hydrochloride for Cardiac & Epigenetic Research

    2026-05-19

    Procainamide Hydrochloride: Applied Workflows for Cardiac and Epigenetic Research

    Principles and Setup: Beyond Classic Sodium Channel Blockade

    Procainamide Hydrochloride (CAS No. 614-39-1) has long been established as a benchmark cardiac sodium channel blocker, primarily targeting Nav1.5 with an IC50 of 3–10 μM. Its classic use in ventricular tachycardia research and antiarrhythmic assays is well-documented, but recent literature and reference studies reveal a broader experimental landscape. Not only does it modulate action potential conduction in cardiomyocytes, but it also suppresses neutrophil activation, inhibits DNA methyltransferase 1 (DNMT1), and even induces cellular vacuolization. These diverse mechanisms unlock applications from high-fidelity cardiac electrophysiology research to epigenetic and immunology workflows.

    From an operational perspective, Procainamide Hydrochloride is a water-soluble solid with robust solubility in DMSO (≥13.65 mg/mL), ethanol (≥22.65 mg/mL), and water (≥46.4 mg/mL), allowing flexible protocol integration. Its purity (98.21%) and rigorous QC—verified by HPLC and NMR—further ensure reproducibility, a key requirement for both high-throughput screening and translational studies.

    Step-by-Step Experimental Workflow: Enhanced Protocols

    Optimizing protocols for procainamide hydrochloride involves leveraging its dual-action capabilities while ensuring compound stability and assay reproducibility. Below is an integrated workflow for use in cardiac and epigenetic models, drawing on published methodologies and product specifications:

    Protocol Parameters

    • Electrophysiology dosing: Prepare working solutions at 3–10 μM in extracellular buffer; apply to cultured cardiomyocytes for 10–20 minutes before recording action potentials to achieve effective Nav1.5 channel blockade (protocol reference).
    • Epigenetic modulation: Treat adherent cell lines with 50 μM Procainamide Hydrochloride dissolved in sterile water or DMSO for 24–72 hours to inhibit DNMT1 and demethylate tumor suppressor genes (details).
    • Storage and stability: Stock solutions (10–50 mM) should be prepared in water or DMSO and stored at -20°C; avoid freeze-thaw cycles and use aliquots within one week for maximal potency as per the manufacturer's recommendations.

    For combinatorial delivery, such as liposomal co-encapsulation with cisplatin, maintain a molar ratio of 1:1 and incubate at 37°C for 30 minutes before downstream cellular assays. This approach has been shown to enhance antiproliferative activity while reducing off-target toxicity (article extension).

    Key Innovation from the Reference Study

    The reference study pioneered a phenotypic small-molecule screen targeting SPP1High tumor-associated macrophages (TAMs), spotlighting the translational potential of targeted epigenetic and immunomodulatory interventions. While the lead compound was not procainamide, the work demonstrates the practical value of using selective inhibitors—such as DNMT1 inhibitors—for reprogramming myeloid cell phenotypes. In experimental terms, this validates the inclusion of Procainamide Hydrochloride in screening panels where immunosuppressive or pro-tumorigenic myeloid populations are implicated, especially given its proven inhibition of DNA methyltransferase 1 and suppression of neutrophil activation.

    Practically, researchers can adapt similar phenotypic screening strategies by integrating procainamide into cell-based assays with SPP1 or related markers as endpoints, paralleling the reference workflow for high-content immuno-oncology screens.

    Advanced Applications and Comparative Advantages

    Procainamide Hydrochloride’s versatility is underscored in several advanced research domains:

    • Cardiac Electrophysiology: Its well-characterized IC50 enables reproducible blockade of Nav1.5, facilitating mechanistic studies of arrhythmogenesis and drug-induced proarrhythmic risk (see protocol optimization).
    • Epigenetic Modulation: By inhibiting DNMT1, procainamide reliably induces demethylation of silenced tumor suppressor genes, supporting functional genomics screens and epigenetic drug discovery (article extension).
    • Immunomodulation: The compound’s ability to suppress neutrophil activation and cytokine release offers a route to dissect inflammatory pathways relevant to both cardiac and oncology models.
    • Combinatorial Chemoprotection: Notably, co-administration with cisplatin in rodent models significantly reduces hepatotoxicity, reflecting a mechanistic shift in platinum biodistribution and unlocking safer chemotherapeutic regimens (study details).

    This multipotency sets Procainamide Hydrochloride apart from traditional single-target sodium channel blockers, particularly in workflows demanding both electrophysiological precision and epigenetic flexibility. According to troubleshooting guides, the lot-to-lot consistency and documentation from APExBIO further enhance data reproducibility across cell-based and tissue assays.

    Troubleshooting and Optimization Tips

    • Solubility Issues: For high-concentration applications (≥10 mM), dissolve procainamide in DMSO or water with gentle vortexing. If precipitation occurs, gently heat to 37°C and re-vortex. Always visually inspect for complete dissolution before use.
    • Assay Interference: Avoid using colored cell culture media or phenol red, as procainamide can fluoresce weakly and may interfere with some readouts. Use clear, serum-free media for optical or fluorescence-based endpoints.
    • Batch Variability: Confirm compound identity and purity with in-house HPLC or LC-MS when developing new workflows. APExBIO provides batch-level documentation, but additional verification is recommended for critical path studies.
    • Stability Concerns: Prepare aliquots for single-use; repeated freeze-thaw cycles can degrade activity. Discard any thawed aliquot not used within 24 hours for most sensitive applications.
    • DNMT1 Inhibition Optimization: For robust DNA methylation assays, pre-validate procainamide’s efficacy using positive demethylation controls and methylation-specific PCR quantification.

    Interlinking Related Resources: Integrated Research Insights

    The landscape of procainamide hydrochloride research is rapidly evolving. For example, the liposomal co-delivery study complements the current workflow by demonstrating enhanced antiproliferative activity and reduced toxicity in oncology models, extending procainamide’s value beyond cardiac research. Meanwhile, the applied workflow guide provides protocol refinements for both cardiac and epigenetic assays, highlighting best practices for reproducibility. The troubleshooting resource directly addresses common bench challenges—such as solubility management and cytotoxicity quantification—empowering researchers with actionable solutions validated by APExBIO’s quality standards.

    Future Outlook: Toward Reproducible and Translational Research

    The convergence of electrophysiological, epigenetic, and immunomodulatory research domains—exemplified by the reference study—positions procainamide hydrochloride as a versatile asset in next-generation assay development. Its dual action as a cardiac sodium channel blocker and DNMT1 inhibitor not only enhances mechanistic studies but also lays the groundwork for combinatorial therapy and chemoprotection workflows.

    As small molecule screening paradigms mature, integrating compounds like Procainamide Hydrochloride into SPP1- and immune cell-focused assays will refine phenotypic discovery and accelerate translation from bench to bedside. The continued commitment by APExBIO to quality and documentation ensures that biomedical researchers can trust this reagent for robust, reproducible results across diverse platforms.